Ezra's Notes Checked November 16, 2026
Investor Holdings

By @ezracrangle

← Seth Klarman, latest 13F

Seth Klarman · Q4 2017

Baupost Group

Portfolio at the end of Q4 2017, from the 13F filed February 13, 2018. See the filing on EDGAR ↗

CompanyWeightValueSharesPriceHeld sinceChange
Synchrony SYF · history 11.2% $1.13B 29,295,030 $38.61 Q3 2016 No change
Cheniere Energy LNG · history 11.0% $1.12B 20,726,340 $53.84 Q1 2014 No change
Viasat VSAT · history 9.7% $984.9M 13,158,137 $74.85 Q2 2013 or earlier No change
Twenty-First Century Fox FOXA · history 7.6% $769.6M 22,288,731 $34.53 Q3 2015 Add 16%
Time Warner TWX · history 7.3% $740.9M 8,100,000 $91.47 Q4 2017 Buy
Allergan AGN · history 7.3% $736.1M 4,500,000 $163.58 Q1 2016 Add 52%
Qorvo QRVO · history 7.2% $732.6M 11,000,000 $66.60 Q1 2017 Add 22%
Colony NorthStar CLNS · history 5.4% $546.6M 47,905,461 $11.41 Q1 2017 No change
Antero Resources AR · history 4.6% $469.7M 24,722,187 $19.00 Q3 2014 Add 3%
PBF Energy PBF · history 3.8% $387.3M 10,924,175 $35.45 Q3 2013 Reduce 31%
Twenty-First Century Fox FOX · history 3.6% $359.3M 10,531,258 $34.12 Q3 2015 Add 43%
Pioneer Natural Resources PXD · history 3.4% $345.7M 2,000,000 $172.85 Q3 2017 Add 6822%
Cardinal Health CAH · history 3.1% $312.5M 5,100,000 $61.27 Q4 2016 Add 102%
Theravance Biopharma TBPH · history 2.6% $259.6M 9,309,168 $27.89 Q2 2014 No change
McKesson MCK · history 2.1% $212.1M 1,360,000 $155.95 Q3 2017 Add 172%
Express Scripts ESRX · history 1.7% $172.2M 2,306,456 $74.64 Q1 2017 Reduce 10%
Cencora COR · history 1.3% $131.7M 1,434,565 $91.82 Q3 2017 Add 660%
Keryx Biopharmaceuticals KERX · history 1.2% $119.9M 25,791,678 $4.65 Q1 2014 No change
Veritiv VRTV · history 1.0% $105.2M 3,641,485 $28.90 Q3 2014 Add 19%
Atara Biotherapeutics ATRA · history 1.0% $97.0M 5,359,632 $18.10 Q4 2014 No change
AMC Entertainment AMC · history 0.7% $75.5M 5,000,000 $15.10 Q3 2017 Add 40%
GTY Technology GTYH.U · units · history 0.4% $45.4M 4,400,000 $10.31 Q4 2016 No change
Paratek Pharmaceuticals PRTK · history 0.4% $42.9M 2,394,498 $17.90 Q4 2014 No change
Novagold Resources NG · history 0.4% $42.2M 10,742,835 $3.93 Q2 2013 or earlier Add 13%
Theravance Biopharma TBPH.CV · convertible notes · history 0.3% $33.0M 30,000,000 prn Q4 2016 No change
Cascadian Therapeutics CASC · history 0.3% $32.3M 8,721,079 $3.70 Q2 2016 No change
ChipMOS IMOS · history 0.3% $26.0M 1,470,408 $17.65 Q2 2013 or earlier Reduce 52%
Saban Capital Acquisition SCAC · history 0.2% $23.1M 2,326,500 $9.93 Q4 2016 No change
Sunrun RUN · history 0.2% $16.8M 2,848,082 $5.90 Q3 2015 No change
Sentinel Energy Services STNL.U · units · history 0.2% $16.0M 1,600,000 $9.97 Q4 2017 Buy
Forward Pharma FWP · history 0.2% $15.4M 4,179,940 $3.68 Q4 2014 Reduce 35%
Trilogy Metals TMQ · history 0.1% $11.5M 10,600,758 $1.08 Q2 2013 or earlier No change
Orexigen Therapeutics OREX · history 0.0% $2.9M 2,226,839 $1.29 Q3 2015 No change
Saban Capital Acquisition SCAC.WS · warrants · history 0.0% $1.4M 1,163,250 $1.24 Q4 2016 No change
34 positions100.0%$10.11B

Weight is the position's share of the total value in this 13F, not of the whole fund. Price is the value divided by the number of shares, so it's the price at the end of the quarter, as the firm reported it. Change compares share counts with Q3 2017, adjusted for stock splits.

Sector weighting

Sector weights in this 13F
Media & telecom29.0%
Energy22.9%
Health care21.4%
Financials & real estate17.0%
Technology7.9%
Industrials1.2%
Materials0.5%

What changed from Q3 2017

← Q3 2017 Q1 2018 →